Loading
A phase 1/2 trial of Venetoclax, Gilteritinib, Azacitidine in multiple myeloma, run by Sumitomo Pharma America, Inc., now recruiting.
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1) is a phase 1/2 interventional study registered as NCT04988555 by Sumitomo Pharma America, Inc., with 606 participants planned, started 2022-02-28 and due to reach its primary completion in 2027-06-30. Interventions recorded: Enzomenib, azoles, Venetoclax, Gilteritinib, Azacitidine (AZA). Conditions listed: Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute, Multiple Myeloma, Myelodysplastic Syndromes. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Gilteritinib, Azacitidine, Venetoclax.
Shares Gilteritinib, Azacitidine, Venetoclax.
Shares Azacitidine, Venetoclax, Multiple myeloma.
Shares Azacitidine, Venetoclax.
Shares Azacitidine, Venetoclax.
Shares Azacitidine, Venetoclax.
Shares Venetoclax, Multiple myeloma.
Shares Azacitidine, Venetoclax.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/